Archive

CHEPLAPHARM donates over €200,000 for Christmas

 

This year CHEPLAPHARM donates €200,000 for the association Deutsch-Afrikanische Zusammenarbeit e.V. and 4.000€ for the Christmas Campaign of the…

Read more  /  pdf

CHEPLAPHARM proves its vigour

 

Cheplapharm successfully closes the first project with LEO Pharma

 

This week CHEPLAPHARM successfully closed the project with LeoPharma, which…

Read more  /  pdf

CHEPLAPHARM closes another product portfolio acquisition

 

This week Cheplapharm closed another deal of a product bundle which contains six molecules and 12 related brands, focused on the treatment of…

Read more  /  pdf

CHEPLAPHARM succeeds again: 1 Billion Euros (equivalent) of Senior Secured Notes placed with institutional Investors

CHEPLAPHARM Arzneimittel GmbH has successfully gained a foothold in the US American institutional bond market.

Read more  /  pdf

CHEPLAPHARM announces pricing of Senior Secured Notes

CHEPLAPHARM Arzneimittel GmbH Announces Pricing of

€575 Million 4.375% Senior Secured Notes due 2028

$500 Million 5.500% Senior Secured Notes due…

Read more  /  pdf

CHEPLAPHARM moves into new building and issues inaugural bond

Almost a year after the topping-out ceremony in March 2019, the extension at the companies headquarters in Greifswald (Ziegelhof) is ready for…

Read more  /  pdf

CHEPLAPHARM buys the rights for Seroquel® and Seroquel XR® in Europe (excluding the UK) and North America

Greifswald, 01/31/2020 – AstraZeneca and CHEPLAPHARM have agreed to transfer the commercial rights for SEROQUEL® and other related brands for the…

Read more  /  pdf

CHEPLAPHARM’s successful institutional bond debut: 500 million euros of senior secured notes at 3.500% placed with institutional investors

CHEPLAPHARM Arzneimittel GmbH, a repeat issuer in the long-term loan market with 980 million euros of institutional term loan (“TLB”) outstanding,…

Read more  /  pdf

CHEPLAPHARM announces pricing of Senior Secured Notes

Cheplapharm has priced €500 million aggregate principal amount of its 3.500% senior secured notes due 2027 (the “Notes”), at an offering price of…

Read more  /  pdf

CHEPLAPHARM announces offering of Senior Secured Notes

Cheplapharm Arzneimittel GmbH has launched an offering of €400 million aggregate principal amount of senior secured notes due 2027.

Read more  /  pdf

CHEPLAPHARM strengthens its relationship with AstraZeneca by acquiring the global commercial rights to LOSEC®

AstraZeneca has agreed to sell the global commercial rights - excluding China, Japan, the U.S. and Mexico - to LOSEC® (omeprazole) and associated…

Read more  /  pdf

Minister-President Schwesig visits CHEPLAPHARM

Schwerin/Greifswald (DE), 07/26/2019 – As part of her summer tour through Mecklenburg-Western Pomerania, Minister-President Manuela Schwesig stops by…

Read more  /  pdf

CHEPLAPHARM's third capital market transaction five times oversubscribed

London/Greifswald, June 13, 2019 – CHEPLAPHARM Arzneimittel GmbH very successfully closed its third capital markets transaction within just one year.…

Read more  /  pdf

Axia Best Managed Company Award goes to CHEPLAPHARM

Düsseldorf/Greifswald (DE), May 10, 2019 – CHEPLAPHARM Arzneimittel GmbH received the "Axia Best Managed Companies Award" (Axia BMC Award) yesterday.…

Read more  /  pdf

CHEPLAPHARM celebrates topping-out ceremony

Just in time with the arrival of spring, CHEPLAPHARM Arzneimittel GmbH is celebrating the topping-out ceremony for the extension building at its…

Read more  /  pdf

By taking over the product rights for DORMICUM® and LEXOTAN®, CHEPLAPHARM closes the very successful fiscal year 2018

 

"As a perfect addition to an already extremely positive year for CHEPLAPHARM, we were able to start another large project in 2018 with F.…

Read more  /  pdf

CHEPLAPHARM places additional € 300 million capital market loan in London with Institutional Investors

Following a successful roadshow with Institutional Investors in London, CHEPLAPHARM Arzneimittel GmbH was able to issue another loan (TLB market) in…

Read more  /  pdf

CHEPLAPHARM acquires product package from Bristol-Myers Squibb – significant expansion of our portfolio

CHEPLAPHARM Arzneimittel GmbH continues its successful expansion strategy by purchasing three further global niche products.

Read more  /  pdf

CHEPLAPHARM acquires global rights to Questran® from Bristol-Myers Squibb

CHEPLAPHARM Arzneimittel GmbH continues with its diversification strategy.

Read more  /  pdf

CHEPLAPHARM acquires product rights for ATACAND® and ATACAND® Plus from AstraZeneca in Europe

CHEPLAPHARM is pleased to announce the acquisition of the commercial rights to ATACAND® (Candesartan Cilexetil) and ATACAND® Plus (fixed-dose…

Read more  /  pdf

CHEPLAPHARM invests 6 million euros in the expansion of its German headquarters in Greifswald – funded by own sources only

From August 2018, CHEPLAPHARM expands its Ziegelhof headquarters in the Hanseatic city of Greifswald with a new building on an area of 5,300 square…

Read more  /  pdf

CHEPLAPHARM’s successful Capital Markets debut: 780 million euros new lending facilities agreed and thus future financing sources secured

CHPLAPHARM Arzneimittel GmbH has successfully completed the refinancing of existing loans and promissory notes.

Read more  /  pdf

CHEPLAPHARM steps into Therapeutic Area on a large-scale

By acquiring the worldwide rights (except US) for the product VISUDYNE® from the Swiss Novartis Pharma AG, CHEPLAPHARM is now active in the…

Read more  /  pdf

CHEPLAPHARM receives credit ratings: A premiere for a medium-sized company in Mecklenburg-Western Pomerania

In the course of an external credit rating, CHEPLAPHARM is rated B/B1 - and thus stable future outlooks.

Read more  /  pdf

CHEPLAPHARM further enhances its portfolio in the Cardiology area

CHEPLAPHARM Arzneimittel GmbH is pleased to announce that we have signed definitive agreements with Bristol-Myers Squibb to acquire product SOTALEX®.

Read more  /  pdf

CHEPLAPHARM continues its expansion course and complements its portfolio with four further products

Right at the beginning of the year, the fast-growing pharmaceutical company CHEPLAPHARM Arzneimittel GmbH secures the product rights for CYMEVENE®,…

Read more  /  pdf

CHEPLAPHARM engaged DKSH to market its regional business in several Asian countries

Zurich (CH) / Greifswald (DE), December 15, 2017 – In a formal ceremony at the DKSH headquarters in Zurich, DKSH and CHEPLAPHARM Arzneimittel GmbH…

Read more  /  pdf

CHEPLAPHARM reached the final phase of the Axia Awards

According to the motto “We are creating a future with perspectives”, mid-sized companies were honored for their sustainable and successful management…

Read more  /  pdf

CHEPLAPHARM plans further investments

On the occasion of the visit of the German Chancellor Angela Merkel and the Minister of Economics Harry Glawe at CHEPLAPHARM in Greifswald, CEO…

Read more  /  pdf

Mysimba®: Commercialization and distributorship arrangement with Orexigen Therapeutics Ireland, Ltd.

The wholly owned subsidiary of Orexigen Therapeutics, Inc. (OREX), and CHEPLAPHARM Arzneimittel GmbH have executed a distributorship agreement…

Read more  /  pdf

50 new employees: CHEPLAPHARM’s successful story continues

The successful company from Greifswald, CHEPLAPHARM Arzneimittel GmbH, continues to grow: 50 new employees have been recruited in the past eight…

Read more  /  pdf

Largest private sector investment in Mecklenburg-Western Pomerania: CHEPLAPHARM makes the megadeal

With an investment of approximately 340 million euros, CHEPLAPHARM Arzneimittel GmbH breaks all private sector records in Mecklenburg-Western…

Read more  /  pdf

CHEPLAPHARM acquires product rights for ANEXATE® from F. Hofmann-La Roche

Amount of investment in the mid, double-digit million euro range. CHEPLAPHARM creates eight new jobs with this acquisition.

Read more  /  pdf

CHEPLAPHARM moves into new 2500 square meter office building at Greifswald’s Business Park Ziegelhof

On December 1st CHEPLAPHARM Arzneimittel GmbH moved into a new prestigious office building at Ziegelhof Business Park in the outskirts of the…

Read more

CHEPLAPHARM Arzneimittel GmbH launches 100 million EURO investment program

The pharmaceutical firm CHEPLAPHARM Arzneimittel GmbH has embarked on the biggest ever investment program in the history of the company.

This…

Read more

CHEPLAPHARM continues its rapid growth: 50% sales increase in 2013 compared to the previous year.

Additionally, CHEPLAPHARM acquires Glenwood LLC based in New York, USA.

CHEPLAPHARM continues its rapid growth in 2013. The increase in sales…

Read more

CHEPLAPHARM acquires the rights for VESANOID® and ROHYPNOL® - largest investment since company´s existence.

Products are attained from F. Hoffmann-La Roche and will be exported to more than 90 countries.

Mesekenhagen-based CHEPLAPHARM Arzneimittel GmbH from…

Read more

CHEPLAPHARM attains the rights for HEMINEVRIN®/DISTRANEURIN®

Pharmaceutical product was taken over from AstraZeneca and is distributed in Europe

CHEPLAPHARM, headquartered in Mesekenhagen (Mecklenburg-Western…

Read more